(Q50992726)

26 March 2018

editorial

0 references

title

Recombinant human activated protein C as a therapy for severe sepsis: lessons learned? (English)

1 reference

26 March 2018

1 reference

1 reference

1 reference

Steven M Opal

1

1 reference

26 March 2018

Steven P LaRosa

series ordinal

2

1 reference

26 March 2018

language of work or name

English

0 references

publication date

1 May 2013

1 reference

26 March 2018

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

26 March 2018

volume

187

1 reference

26 March 2018

issue

10

1 reference

26 March 2018

page(s)

1041-1043

1 reference

26 March 2018

Drotrecogin alfa (activated) in adults with septic shock.

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: a meta-analysis and metaregression

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

The clinical evaluation committee in a large multicenter phase 3 trial of drotrecogin alfa (activated) in patients with severe sepsis (PROWESS): Role, methodology, and results*

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

Early lactate clearance is associated with improved outcome in severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

Multicenter study of early lactate clearance as a determinant of survival in patients with presumed sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

Effects of drotrecogin alfa (activated) in human endotoxemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

Genomic responses in mouse models poorly mimic human inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

Recombinant Human Activated Protein C for Adults with Septic Shock. A Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.201303-0505ED

10.1164/RCCM.201303-0505ED

21 January 2018

Identifiers

DOI

1 reference

26 March 2018

1 reference

26 March 2018